Novartis says has no intention of buying Actavis
ZURICH (Reuters) - Novartis has no plans to bid for U.S.-based generic drugmaker Actavis, which is the subject of intense takeover s...
Read More »Health News
Subscribe to the Health News feed.-
-
Bayer to acquire herbal medicine maker Steigerwald
FRANKFURT (Reuters) - Germany's largest drugmaker Bayer said it agreed to buy privately held Steigerwald Arzneimittelwerk GmbH, a ma...
Read More » -
AstraZeneca accelerates cancer drug testing
By Ben Hirschler LONDON (Reuters) - AstraZeneca has enrolled the first patient into a final-stage clinical trial of a new drug for a...
Read More » -
China steps up inspection of meat trade after fake lamb scandal
BEIJING (Reuters) - China has begun a crackdown on the sales of fake, diseased and tainted meat products after a series of scandals ...
Read More » -
Medical weed could jinx recreational dope market in Washington state
By Jonathan Kaminsky OLYMPIA, Washington (Reuters) - Key officials helping to create Washington state's potentially lucrative recrea...
Read More » -
MRI scans could make baby autopsies more acceptable
By Kate Kelland LONDON (Reuters) - Bereaved parents who do not want to see their dead babies go through a conventional autopsy could...
Read More » -
U.S. advisory on mercury in fish tied up at health department
By Toni Clarke WASHINGTON (Reuters) - Updated federal advice on mercury levels in fish appears to have stalled within the U.S. depar...
Read More » -
New cancer tools allow patients to reconsider chemo
By Deena Beasley LOS ANGELES (Reuters) - After decades of using one-size-fits-all therapies to combat cancer, doctors are using new ...
Read More » -
WHO reports first patient-to-nurse spread of new SARS-like virus
By Kate Kelland LONDON (Reuters) - Two health workers in Saudi Arabia have become infected with a potentially fatal new SARS-like vi...
Read More » -
Bristol melanoma drug combo marks new advance in immunotherapy
By Julie Steenhuysen CHICAGO (Reuters) - Melanoma patients treated with two Bristol-Myers Squibb drugs fared much better than those ...
Read More »